Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.46 |
| ▸ | WNT1 | P04628 | 3/20 | 0.46 |
| ▸ | KDM1A | O60341 | 5/20 | 0.46 |
| ▸ | CD38 | P28907 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25136182 | 0.88 | SCN9A (0.45) | GSK3BDYRK1AWNT1KDM1ACD38 | |
| SCHEMBL25474638 | 0.88 | ALDH1A1 (0.47) | CD38CNR1 | |
| SCHEMBL25135997 | 0.87 | GSK3B (0.43) | GSK3BDYRK1AWNT1KDM1ACD38 | |
| SCHEMBL30363954 | 0.86 | CD38 (0.43) | CD38CNR1 | |
| SCHEMBL29182188 | 0.86 | CD38 (0.43) | CD38CNR1 | |
| SCHEMBL25136180 | 0.86 | CD38 (0.43) | CD38CNR1 | |
| SCHEMBL25136420 | 0.86 | GSK3B (0.39) | GSK3BDYRK1AWNT1 | |
| SCHEMBL25136113 | 0.85 | CD38 (0.59) | GSK3BDYRK1AWNT1KDM1ACD38 | |
| SCHEMBL25135979 | 0.85 | GSK3B (0.41) | GSK3BDYRK1AWNT1KDM1ACD38 | |
| SCHEMBL25136297 | 0.84 | ALDH1A1 (0.40) | GSK3BDYRK1AWNT1CD38 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | GSK3B 395/4885DYRK1A 1430/4885WNT1 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.